- Home
- VCRE vs OABI Comparison
VCRE vs OABI Comparison
Compare VCRE & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VCRE | OABI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.4M | 294.3M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VCRE | OABI |
|---|---|---|
| Price | $9.80 | $4.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 12.0K | ★ 1.4M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.03 | $1.32 |
| 52 Week High | $13.15 | $5.43 |
Technical Indicators
Market Signals| Indicator | VCRE | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 66.14 |
| Support Level | N/A | $1.90 |
| Resistance Level | $13.00 | $5.43 |
| Average True Range (ATR) | 0.55 | 0.25 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 9.43 | 83.19 |
Price Performance
Historical ComparisonAbout VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.